The OLEUM project will generate innovative, more effective and harmonized analytical solutions to detect and fight the most common and emerging frauds and to verify the overall quality of olive oils (OOs). By a core group of 20 partners from 15 countries OLEUM will undertake RESEARCH ACTIVITIES based on the development of IMPROVED and NEW ANALYTICAL METHODS by targeted and omics approaches with the aim: i) to detect new markers of the soft deodorization process; ii) to discover illegal blends between OOs and other vegetable oils; iii) to control OO quality (e.g. freshness); iv) to improve the organoleptic assessment with a Quantitative Panel Test, based on current official methods, and supported by tailored reference materials for better calibration of the sensory panels coupled with rapid screening tools to facilitate the work of the panelists. The most promising OLEUM solutions will be subjected to VALIDATION in conformity with internationally agreed standards by peer laboratories. OLEUM will recreate a realistic “deodorization scenario” by producing tailored, soft deodorized OOs by lab-scale and up-scaled pilot plants to apply analytical solutions to known samples. Substantial KNOWLEDGE and TECHNOLOGY TRANSFER activities will be envisaged to aid in implementation of: a) a web-based easily-accessible, scalable and constantly updated OLEUM DATABANK, containing all the information from OLEUM research and other reliable international sources, will be available for download data and spectra and to help achieve satisfactory harmonization of analytical approaches among control laboratories; b) the OLEUM NETWORK of relevant OOs stakeholders to maximize the impact of proposed analytical solutions. Finally, a robust dissemination strategy by the OLEUM project aimed at effectively sharing results with all stakeholders in the OO supply chain has the potential to improve consumer and market confidence, and preserve the image of OOs on a global scale.

The vision of FutureFoodS is to collectively achieve environmentally-friendly, socially secure, fair and economically viable healthy and safe Food Systems (FS) for Europe. FutureFoodS gather 87 partners from 22 EU Member States, 6 Associated Countries and 1 third country. FutureFoodS includes public and private actors, policy makers, foundations, locally, sub-nationally, nationally, EU-widely. All these FutureFoodS partners are fully aligned on the vision for the Partnership and the methodology for its implementation in line with SDG17 and EU Green Deal components. This vision has been broken down into general (GO), specific (SO) and operational (OO) objectives applying across the 4 R&I areas and 4 transversal activities identified by the FutureFoods consortium in its stable draft Strategic Research and Innovation Agenda (SRIA) which constitutes the strategic backbone of the project. The four GO cover: GO1 - Functioning of FS; GO2 - System approaches; GO3 - Inclusive government; GO4 - Co-creation cases. These GO have then been translated into SO prioritised in line with the timescale and resources of the Partnership: SO1 - Change the way we eat; SO2- Change the way we process and supply food, SO3 - Change the way we connect with FSs and SO4 - Change the way we govern FS. In addition, 6 interconnected OO have been set: OO1- Pooling R&I resources and programming; OO2 - Operational FS Observatory; OO3 - Active FS knowledge Hub of FS Labs; OO4 - Functioning knowledge sharing and scaling mechanisms; OO5- Revisiting the SRIA; OO6 - Promoting, supporting, widening & gathering FS various communities. The objectives implemented in the 8 WPs of FutureFoodS will exert impact directly or indirectly in most of the destinations of Horizon Europe’s Cluster 6 2023-2024 work programme and particularly for the topic destination ‘Fair, healthy and environment-friendly FS from primary production to consumption’ echoing to the main EU and World FS policies & strategies.

In recent years, nucleic acids (NAs) have contributed significantly to advancing the diagnosis and treatment of diseases such as cancer, infectious and rare diseases. Breakthrough technologies like genome editing tool CRISPR/Cas9, direct RNA sequencing, multi-omics analysis procedure for NAs analysis, bioinformatics and machine learning for data analysis, and targeted delivery systems based on lipid nanoparticles (LNPs) prove the increasing interest in NAs applicability. However, the full potential of NAs is yet to be unlocked, and the translation of NAs into clinical practice is still facing many methodological and technological limitations such as low detection sensitivity, limited sequencing capacity, lack of analytical methods for NAs therapeutics, and inadequate in vivo delivery. INT2ACT brings together 6 academic research units and 5 industrial partners to address these limitations by establishing new methods for detecting and analysing NAs in patient liquid biopsies, boosting available procedures for direct RNA sequencing, developing new methods for the synthesis and analysis of antisense oligonucleotides (ASO) libraries, identifying new RNA targets, and optimise NA therapeutics delivery systems. The concept of harnessing NAs in the realm of medicine opens doors to an array of possibilities, including the development of therapeutic vaccines for cancer and innovative ASO-based therapies for addressing a multitude of genetic disorders. While advancing NAs’ research and technologies, INT2ACT will also contribute to forming the next generation of highly skilled experts through an interdisciplinary and intersectoral training programme delivered to 15 Doctoral Candidates. The network-wide training programme is designed to ensure that all INT2ACT fellows will have the skills for a successful career in or outside of research in any sector.

Antimicrobial resistance (AMR) is an increasing threat to effectively treat serious bacterial infections. To this end, tailoring antibiotic treatments to individual patients is urgently needed to maximize efficacy while minimizing the risk of promoting further resistance. To enable development of innovative personalized antibiotic treatment strategies, quantitative understanding of the interplay between drug, pathogen and host is crucial. The Training towards Innovative Personalized Antibiotic Therapy (TIPAT) network will train inter-disciplinary specialists optimally equipped with a skill set to address this challenge. TIPAT offers a cutting-edge training-by-research programme for 15 Early Stage Researchers (ESRs) who will investigate translation and integration of biological and pharmacological data related to drug-pathogen-host interactions towards personalized therapies. Central to the TIPAT research and training program is the combination of state-of-the art quantitative modelling with approaches in clinical pharmacology, immunology and microbiology, which enables development of innovative methodology to personalized antibiotic therapies. The consortium unites a cross-disciplinary team of leading academic experts and inter-sectoral partners including SMEs, pharmaceutical companies and hospitals. Secondments complementary to ESR research projects will promote inter-professional and cross-disciplinary research and communication. The TIPAT integrated program is enriched with transferable, regulatory and entrepreneurial skills training delivered through themed Summer and Winter schools. The TIPAT network will deliver inter-disciplinary specialists in personalized antibiotic treatment strategies. The TIPAT training will strongly expand career perspectives of ESRs in academia, hospitals, industry or regulatory agencies, and develop scientific innovations to enable optimal therapy for individual patients to address current and future challenges of AMR-infections.